Herpes infections are common among women of reproductive age (i.e., aged 15-44 years).1 Acyclovir (Zovirax Registered*), an antiviral drug effective in the treatment of herpes simplex infection, was approved by the Food and Drug Administration (FDA) in 1984. Since its approval, the effects of acyclovir on human pregnancies have not been determined. However, inadvertent pregnancy exposures to acyclovir were expected to occur among women in whom treatment had been indicated for preexisting herpes simplex infections. Some physicians have reported intentional use of acyclovir during pregnancy for treatment of life-threatening herpes simplex infection.** To assess the outcomes of pregnancies exposed to acyclovir, the Acyclovir in Pregnancy Registry was established on June 1, 1984, by the manufacturer, in collaboration with CDC. This report summarizes data on pregnancies reported to the registry through June 30, 1993.
The registry is managed by the Burroughs Wellcome Co. (Research Triangle Park, North Carolina)—the manufacturer of the drug—with oversight from an advisory committee with representation from CDC, a county health agency, and Burroughs Wellcome Co. ; committee members have
Pregnancy Outcomes Following Systemic Prenatal Acyclovir Exposure—June 1, 1984-June 30, 1993. Arch Dermatol. 1994;130(2):153-154. doi:10.1001/archderm.1994.01690020017002